Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Novo Nordisk’s parent company said will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection Wegovy and diabetes shot Ozempic.
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk’s Wegovy.